
Rising costs in cancer care have fueled a national conversation on how to decide whether today’s new therapies are “worth it.” A supplement of Evidence-Based Oncology features interviews with those developing value frameworks and coverage of the Oncology Stakeholders Summit, which included patient advocacy, payers and pharmaceutical manufacturers.